different metal complexes and propargylic ester substrates
in an effort to understand the mechanisms of these processes.
A particularly successful approach to control initial 5-exo
versus 6-endo nucleophilic attack of the ester carbonyl onto
the alkyne (see 1 f 2 versus 1 f 6) is the introduction of
substituents to electronically modulate the alkyne reactivity.4b,5
While propargylic esters bearing terminal alkynes typically
undergo 5-exo-dig cyclization using Ru, Pt, or Au catalysts,6
internal alkynes bearing alkyl or aryl7 substituents usually
undergo 6-endo-dig cyclization. Malacria was the first to
report that ester substituents at the alkyne terminus lead
exclusively to initial 5-exo-dig cyclization using PtCl2 as the
catalyst.5 We have recently shown that this strategy is
effective for the synthesis of indenes (e.g., 9, Scheme 2) using
propargylic ester substrates such as 7.8
cyclization due to the electron-withdrawing capability of the
2-substituted pyridine at the alkyne terminus. Backbonding
from the metal center (see 11) was expected to yield
metallocarbenoid 12, which upon cyclization (via the inter-
mediacy of zwitterion 13) would yield 2,3-disubstituted
indolizine 14 following proton transfer. Alternatively, in Path
B, initial 6-endo-dig cyclization (should the pyridine sub-
stituent exert electronic effects similar to a phenyl group)
would furnish allene 15, which would react further (via 16)
to form 1,3-disubstituted indolizine 17.
Our group has recently reported a cycloisomerization
transformation for the synthesis of 1,3-disubstituted indol-
izines such as 17.9 However, general methods to synthesize
2,3-disubstituted indolizines (e.g., 14) are limited. Given the
existing challenge of regioselective functionalization of
indolizines,10 the transformation of 10 f 14 would be
especially significant.
The propargylic ester substrate 18a (Table 1), which was
prepared in a one-pot sequence in high overall yield from
Scheme 2. Pt-Catalyzed Indene Formation
Table 1. Optimization Studies
Herein, we report a novel mode of reactivity of propargylic
ester substrates bearing pyridine substituents at the alkyne
terminus that undergo cycloisomerization to produce highly
functionalized indolizine products. During the course of these
studies, we have discovered remote electronic effects of
substituents at the propargylic position to be important in
biasing initial 5-exo versus 6-endo cyclization.
yield (%)
entry substrate catalyst
ligand
additive (ratio 19:20)a
1
2
3
4
5b
6b
7b
18a
18a
18a
18b
18b
18b
18b
PtCl2
PtCl2
PtCl2
PtCl2
PtCl2
PtCl2
PtI2
-
PPh3
-
-
-
-
Lil
LiCl
-
10
-
For example, two possible cycloisomerization pathways
are open to propargylic ester substrate 10 (Scheme 3). Path
P(C6F5)3
P(C6F5)3
P(C6F5)3
P(C6F5)3
P(C6F5)3
42 (3:1)
64 (9:1)
61 (15:1)
42 (9:1)
82 (18:1)
Scheme 3. Proposed 1,3- and 2,3-Disubstituted Indolizine
Formation
a Ratio determinations were made by comparison of 1H NMR resonances.
b Reaction conducted at 80 °C.
the corresponding pyridine acetylene, was used in our initial
optimization studies.11 Using previous Pt(II)-catalyzed cy-
cloisomerization studies from our laboratories as a starting
point, we investigated the effect of combinations of platinum
salts, solvents, and reaction conditions on the efficiency of
the indolizine-forming transformation.
The best initial results were obtained with PtCl2 as a
catalyst and benzene as the solvent, which gave a 10%
conversion with the majority of the mass balance accounted
(8) Prasad, B. A. B.; Yoshimoto, F. K.; Sarpong, R. J. Am. Chem. Soc.
2005, 127, 12468.
A is predicated on the basis of our previous cycloisomer-
ization studies, whereby 10 could undergo initial 5-exo-dig
(9) (a) Smith, C. R.; Bunnelle, E. M.; Rhodes, A. R.; Sarpong, R. Org.
Lett. 2007, 9, 1169. (b) A related report recently appeared: Seregin, I. V.;
Schammel, A. W.; Gevorgyan, V. Org. Lett. 2007, 9, 3433.
(10) (a) Park, C. H.; Ryabova, V.; Seregin, I. V.; Sromek, A. W.;
Gevorgyan, V. Org. Lett. 2004, 6, 1159. (b) Sawada, K.; Okada, S.; Kuroda,
A.; Watanabe, S.; Sawada, Y.; Tanaka, H. Chem. Pharm. Bull. 2001, 49,
799. (c) Ostby, O. B.; Dalhus, B.; Gundersen, L.-L.; Rise, F.; Bast, A.;
Haenen, G. R. M. M. Eur. J. Org. Chem. 2000, 22, 3763.
(5) Cariou, K.; Mainetti, E.; Fensterbank, L.; Malacria, M. Tetrahedron
2004, 60, 9745.
(6) (a) Miki, K.; Ohe, K.; Uemura, S. Tetrahedron Lett. 2003, 44, 2019.
(b) Miki, K.; Ohe, K.; Uemura, S. J. Org. Chem. 2003, 68, 8503.
(7) For earlier discussions, see: (a) Cho, E. J.; Kim, M.; Lee, D. Org.
Lett. 2006, 8, 5413. (b) Marion, N.; Diez-Gonza´lez, S.; de Fre´mont, P.;
Noble, A. R.; Nolan, S. P. Angew. Chem., Int. Ed. 2006, 45, 3647.
(11) For complete synthesis details, see Supporting Information.
4548
Org. Lett., Vol. 9, No. 22, 2007